These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33303577)

  • 1. Management of immune checkpoint therapy for patients with cancer in the face of COVID-19.
    Shen C; Li Q; Wei Y; Li Y; Li J; Tao J
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33303577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
    Ottaviano M; Curvietto M; Rescigno P; Tortora M; Palmieri G; Giannarelli D; Aieta M; Assalone P; Attademo L; Avallone A; Bloise F; Bosso D; Borzillo V; Buono G; Calderoni G; Caputo F; Cartenì G; Cavallero D; Cavo A; Ciardiello F; Conca R; Conteduca V; De Falco S; De Felice M; De Laurentiis M; De Placido P; De Placido S; De Santo I; De Stefano A; Della Corte CM; Di Franco R; Di Lauro V; Fabbrocini A; Federico P; Festino L; Giordano P; Giuliano M; Gridelli C; Grimaldi AM; Lia M; Marretta AL; Massa V; Mennitto A; Merler S; Merz V; Messina C; Messina M; Milano M; Minisini AM; Montesarchio V; Morabito A; Morgillo F; Mucci B; Nappi L; Napolitano F; Paciolla I; Pagliuca M; Palmieri G; Parola S; Pepe S; Petrillo A; Piantedosi F; Piccin L; Picozzi F; Pietroluongo E; Pignata S; Prati V; Riccio V; Rosanova M; Rossi A; Russo A; Salati M; Santabarbara G; Sbrana A; Simeone E; Silvestri A; Spada M; Tarantino P; Taveggia P; Tomei F; Vincenzo T; Trapani D; Trojanello C; Vanella V; Vari S; Ventriglia J; Vitale MG; Vitiello F; Vivaldi C; von Arx C; Zacchi F; Zampiva I; Zivi A; Daniele B; Ascierto PA;
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
    Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
    Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.
    Abid MB
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome.
    Azar MM; Shin JJ; Kang I; Landry M
    Expert Rev Mol Diagn; 2020 Nov; 20(11):1087-1097. PubMed ID: 32990479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R; Theron AJ; Rapoport BL
    Front Immunol; 2019; 10():2254. PubMed ID: 31616428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 and immunological regulations - from basic and translational aspects to clinical implications.
    Schön MP; Berking C; Biedermann T; Buhl T; Erpenbeck L; Eyerich K; Eyerich S; Ghoreschi K; Goebeler M; Ludwig RJ; Schäkel K; Schilling B; Schlapbach C; Stary G; von Stebut E; Steinbrink K
    J Dtsch Dermatol Ges; 2020 Aug; 18(8):795-807. PubMed ID: 32761894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment.
    Rossi E; Schinzari G; Tortora G
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32699182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy.
    Hong R; Zhao H; Wang Y; Chen Y; Cai H; Hu Y; Wei G; Huang H
    Bone Marrow Transplant; 2021 Mar; 56(3):570-580. PubMed ID: 32943758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel.
    Napodano C; Pocino K; Stefanile A; Marino M; Miele L; Gulli F; Basile V; Pandolfi F; Gasbarrini A; Rapaccini GL; Basile U
    Scand J Immunol; 2021 Mar; 93(3):e12977. PubMed ID: 32931622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.
    Mandala M; Lorigan P; De Luca M; Bianchetti A; Merelli B; Bettini AC; Bonomi L; Nahm S; Vitale MG; Negrini G; Di Croce A; Ascierto PA; Rulli E; Tondini CA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy.
    Lee J; Lozano-Ruiz B; Yang FM; Fan DD; Shen L; González-Navajas JM
    Front Immunol; 2021; 12():625667. PubMed ID: 33777008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?
    Talamonti M; Tofani L; Bianchi L; Galluzzo M
    Arch Dermatol Res; 2021 Mar; 313(2):127-128. PubMed ID: 32647977
    [No Abstract]   [Full Text] [Related]  

  • 14. COVID-19 and immune checkpoint inhibitors: initial considerations.
    Sullivan RJ; Johnson DB; Rini BI; Neilan TG; Lovly CM; Moslehi JJ; Reynolds KL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32434790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.
    Yekedüz E; Dursun B; Aydın GÇ; Yazgan SC; Öztürk HH; Azap A; Utkan G; Ürün Y
    J Oncol Pharm Pract; 2020 Jul; 26(5):1289-1294. PubMed ID: 32423324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T Cell Phenotyping in Individuals Hospitalized with COVID-19.
    Rupp J; Dreo B; Gütl K; Fessler J; Moser A; Haditsch B; Schilcher G; Matzkies LM; Steinmetz I; Greinix H; Stradner MH
    J Immunol; 2021 Apr; 206(7):1478-1482. PubMed ID: 33558375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID, Biologics, and Psoriasis Therapy.
    Elston DM
    J Am Acad Dermatol; 2020 Dec; 83(6):1577-1578. PubMed ID: 33051006
    [No Abstract]   [Full Text] [Related]  

  • 18. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
    Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
    Rogiers A; Pires da Silva I; Tentori C; Tondini CA; Grimes JM; Trager MH; Nahm S; Zubiri L; Manos M; Bowling P; Elkrief A; Papneja N; Vitale MG; Rose AAN; Borgers JSW; Roy S; Mangana J; Pimentel Muniz T; Cooksley T; Lupu J; Vaisman A; Saibil SD; Butler MO; Menzies AM; Carlino MS; Erdmann M; Berking C; Zimmer L; Schadendorf D; Pala L; Queirolo P; Posch C; Hauschild A; Dummer R; Haanen J; Blank CU; Robert C; Sullivan RJ; Ascierto PA; Miller WH; Stephen Hodi F; Suijkerbuijk KPM; Reynolds KL; Rahma OE; Lorigan PC; Carvajal RD; Lo S; Mandala M; Long GV
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management.
    Kalisz KR; Ramaiya NH; Laukamp KR; Gupta A
    Radiographics; 2019; 39(7):1923-1937. PubMed ID: 31584861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.